• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

暴露-反应关系中S形E模型的参数估计

Parameter estimation for sigmoid E models in exposure-response relationship.

作者信息

Choe Sangmin, Lee Donghwan

机构信息

Department of Clinical Pharmacology, Pusan National University Hospital, Busan 49241, Republic of Korea.

(Bio)Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.

出版信息

Transl Clin Pharmacol. 2017 Jun;25(2):74-84. doi: 10.12793/tcp.2017.25.2.74. Epub 2017 Jun 15.

DOI:10.12793/tcp.2017.25.2.74
PMID:32133323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7042008/
Abstract

The purpose of this simulation study is to explore the limitation of the population PK/PD analysis using data from a clinical study and to help to construct an appropriate PK/PD design that enable precise and unbiased estimation of both fixed and random PD parameters in PK/PD analysis under different doses and Hill coefficients. Seven escalating doses of virtual drugs with equal potency and efficacy but with five different Hill coefficients were used in simulations of single and multiple dose scenarios with dense sampling design. A total of 70 scenarios with 100 subjects were simulated and estimated 100 times applying 1-compartment PK model and sigmoid E model. The bias and precision of the parameter estimates in each scenario were assessed using relative bias and relative root mean square error. For the single dose scenarios, most PD parameters of sigmoid E model were accurately and precisely estimated when the C was more than 85% of EC, except for typical value and inter-individual variability of EC which were poorly estimated at low Hill coefficients. For the multiple dose studies, the parameter estimation performance was not good. This simulation study demonstrated the effect of the relative range of sampled concentrations to EC and sigmoidicity on the parameter estimation performance using dense sampling design.

摘要

本模拟研究的目的是探讨利用临床研究数据进行群体药代动力学/药效学(PK/PD)分析的局限性,并帮助构建合适的PK/PD设计,以便在不同剂量和希尔系数下,在PK/PD分析中对固定和随机的PD参数进行精确且无偏估计。在单剂量和多剂量方案的模拟中,使用了七种剂量递增的虚拟药物,这些药物具有相同的效力和功效,但具有五个不同的希尔系数,并采用密集采样设计。总共模拟了70种情况,每种情况有100名受试者,并应用单室PK模型和S型E模型进行了100次估计。使用相对偏差和相对均方根误差评估每种情况下参数估计的偏差和精度。对于单剂量方案,当血药浓度(C)超过半数效应浓度(EC)的85%时,S型E模型的大多数PD参数能够得到准确且精确的估计,但在低希尔系数下,EC的典型值和个体间变异性估计较差。对于多剂量研究,参数估计性能不佳。本模拟研究证明了采样浓度与EC的相对范围以及S型特性对使用密集采样设计的参数估计性能的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/f28e0e245cb3/tcp-25-74-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/2a7b91af0acf/tcp-25-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/ad615a65189f/tcp-25-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/f28e0e245cb3/tcp-25-74-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/2a7b91af0acf/tcp-25-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/ad615a65189f/tcp-25-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf6/7042008/f28e0e245cb3/tcp-25-74-g003.jpg

相似文献

1
Parameter estimation for sigmoid E models in exposure-response relationship.暴露-反应关系中S形E模型的参数估计
Transl Clin Pharmacol. 2017 Jun;25(2):74-84. doi: 10.12793/tcp.2017.25.2.74. Epub 2017 Jun 15.
2
Evaluation of mixture modeling with count data using NONMEM.使用NONMEM对计数数据进行混合建模的评估。
J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):167-83. doi: 10.1023/a:1025564409649.
3
Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.基于稀疏采样的群体药效学参数估计:S形曲线对参数估计的影响
AAPS J. 2009 Sep;11(3):535-40. doi: 10.1208/s12248-009-9131-2. Epub 2009 Jul 24.
4
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.
5
Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.群体药代动力学/药效学数据的同步分析与序贯分析II:方法的稳健性
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16. doi: 10.1023/b:jopa.0000012999.36063.4e.
6
Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.大鼠美沙酮镇痛的性别特异性:群体药代动力学和药效学方法。
Pharm Res. 2002 Jun;19(6):858-67. doi: 10.1023/a:1016117218760.
7
Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children.对乙酰氨基酚、布洛芬和安慰剂在儿童中解热作用的药代动力学-药效学整合模型
J Pharmacokinet Biopharm. 1998 Oct;26(5):559-79. doi: 10.1023/a:1023225217108.
8
The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.动静脉浓度差异对药效学参数估计值的影响。
J Pharmacokinet Biopharm. 1997 Feb;25(1):39-62. doi: 10.1023/a:1025767710234.
9
Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.基于靶控药物处置的快速结合近似模型的剂量选择对参数估算的影响。
J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):223-35. doi: 10.1007/s10928-010-9190-0. Epub 2010 Dec 17.
10
Estimation of population pharmacokinetic parameters in the presence of non-compliance.存在不依从性情况下的群体药代动力学参数估计
J Pharmacokinet Pharmacodyn. 2003 Feb;30(1):53-81. doi: 10.1023/a:1023297426153.

引用本文的文献

1
Checkerboard synergistic data analysis using a Hill function-based approach.使用基于希尔函数的方法进行棋盘格协同数据分析。
bioRxiv. 2025 Feb 8:2025.02.05.636765. doi: 10.1101/2025.02.05.636765.
2
Formulation and Validation of an Extended Sigmoid Emax Model in Pharmacodynamics.药效学中扩展S型Emax模型的构建与验证
Pharm Res. 2024 Sep;41(9):1787-1795. doi: 10.1007/s11095-024-03752-9. Epub 2024 Aug 14.
3
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab.

本文引用的文献

1
Basic concepts in population modeling, simulation, and model-based drug development.群体建模、模拟和基于模型的药物研发的基本概念。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e6. doi: 10.1038/psp.2012.4.
2
Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives.药物计量学在抗感染药物临床开发和药物治疗中的应用。
Expert Rev Clin Pharmacol. 2013 Mar;6(2):159-70. doi: 10.1586/ecp.13.6.
3
Individualization of drug therapy: history, present state, and opportunities for the future.
SB12(拟生物类似药依库珠单抗)与参照药依库珠单抗的群体药代动力学、药效学和疗效建模。
Eur J Clin Pharmacol. 2024 Sep;80(9):1325-1338. doi: 10.1007/s00228-024-03703-8. Epub 2024 May 30.
4
Control Theory and Cancer Chemotherapy: How They Interact.控制理论与癌症化疗:它们如何相互作用。
Front Bioeng Biotechnol. 2021 Jan 14;8:621269. doi: 10.3389/fbioe.2020.621269. eCollection 2020.
5
Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?采样时间对抗生素群体药代动力学分析的影响:为何在第四次给药后采集血样?
Pharmaceuticals (Basel). 2020 Sep 16;13(9):249. doi: 10.3390/ph13090249.
药物治疗个体化:历史、现状与未来机遇。
Clin Pharmacol Ther. 2012 Oct;92(4):458-66. doi: 10.1038/clpt.2012.113. Epub 2012 Sep 5.
4
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.药物计量学分析对新药审批和标签决策的影响:2000 年至 2008 年间 198 项申报的回顾。
Clin Pharmacokinet. 2011 Oct;50(10):627-35. doi: 10.2165/11593210-000000000-00000.
5
Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.基于稀疏采样的群体药效学参数估计:S形曲线对参数估计的影响
AAPS J. 2009 Sep;11(3):535-40. doi: 10.1208/s12248-009-9131-2. Epub 2009 Jul 24.
6
The Hill equation: a review of its capabilities in pharmacological modelling.希尔方程:对其在药理建模中作用的综述
Fundam Clin Pharmacol. 2008 Dec;22(6):633-48. doi: 10.1111/j.1472-8206.2008.00633.x.
7
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.利用先前的定量知识指导药物研发决策和监管科学建议:2004 - 2006年美国食品药品监督管理局(FDA)药物计量学的影响
J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111.
8
Adaptive designs for dose-finding studies based on sigmoid Emax model.基于S形Emax模型的剂量探索研究的适应性设计。
J Biopharm Stat. 2007;17(6):1051-70. doi: 10.1080/10543400701643954.
9
Using disease progression models as a tool to detect drug effect.使用疾病进展模型作为检测药物效果的工具。
Clin Pharmacol Ther. 2007 Jul;82(1):81-6. doi: 10.1038/sj.clpt.6100228. Epub 2007 May 16.
10
Pharmacodynamic parameter estimation: population size versus number of samples.药效学参数估计:总体大小与样本数量
AAPS J. 2005 Oct 5;7(2):46. doi: 10.1208/aapsj070246.